Benchmark Reiterates Speculative Buy on Anebulo Pharmaceuticals, Maintains $8 Price Target
Portfolio Pulse from richadhand@benzinga.com
Benchmark analyst Robert Wasserman reiterated a Speculative Buy rating on Anebulo Pharmaceuticals (NASDAQ:ANEB) and maintained an $8 price target.
May 18, 2023 | 1:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Anebulo Pharmaceuticals (NASDAQ:ANEB) received a Speculative Buy rating from Benchmark analyst Robert Wasserman, with an $8 price target.
The Speculative Buy rating from Benchmark analyst Robert Wasserman indicates a positive outlook for Anebulo Pharmaceuticals. The maintained $8 price target suggests potential upside for the stock. This news is highly relevant and important for investors in ANEB, and the confidence in the analysis is high due to the analyst's reputation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100